title: Optimization of comorbidity therapy to achieve sustained viral response in HCV patients.
abstract: Several studies indicate that insulin resistance and diabetes influence sustained viral response in treatment for chronic HCV infection. We describe the case of a relapsed patient with HCV infection who achieved a sustained viral response due to an improvement in insulin resistance through modification of antihypertensive therapy. By improving insulin resistance with telmisartan, an ARB with PPAR gamma agonist propriety, sustained viral response was obtained with the same antiviral therapy. Optimization of comorbidity therapy is useful for improving the possibility of achieving a sustained viral response.
authors.affiliation: University of Molise, Campobasso, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Ucciferri
authors.forename: Jacopo
authors.initials: J
authors.lastname: Vecchiet
authors.forename: Eligio
authors.initials: E
authors.lastname: Pizzigallo
authors.forename: Katia
authors.initials: K
authors.lastname: Falasca
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007333:Insulin Resistance; D008875:Middle Aged; D047495:PPAR gamma / Q000819:agonists; D000077333:Telmisartan
chemical_list: D000959:Antihypertensive Agents; D000998:Antiviral Agents; D001562:Benzimidazoles; D001565:Benzoates; D047495:PPAR gamma; D000077333:Telmisartan